REAL-WORLD CLINICAL AND VIROLOGICAL OUTCOMES OF UNTREATED AND TENOFOVIR DISOPROXIL FUMARATE (TDF)-TREATED CHRONIC HEPATITIS B (CHB) PREGNANT PATIENTS IN A LOW HEPATITIS B VIRUS (HBV) ENDEMIC REGION

被引：0
|
作者：
Kochaksaraei, Golasa Samadi [1 ]
Shaheen, Abdel Aziz [1 ]
Castillo, Eliana [1 ]
Martin, Steven R. [1 ]
Israelson, Heidi [1 ]
Aspinall, Alex [1 ]
Borman, Meredith A. [1 ]
Congly, Stephen E. [1 ]
Stinton, Laura M. [1 ]
Lee, Samuel S. [1 ]
Coffin, Carla S. [1 ]
机构：
[1] Univ Calgary, Med, Calgary, AB, Canada
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
983
引用
收藏
页码：600A / 601A
页数：2
相关论文
共 50 条
  • [31] Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB)
    Jacobson, Ira M.
    Marcellin, Patrick
    Heathcote, Jenny
    Mathurin, Philippe
    Gane, Ed J.
    Buggisch, Peter
    Husa, Petr
    Krastev, Zahary
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    GASTROENTEROLOGY, 2009, 136 (05) : A867 - A867
  • [32] The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)
    Afdhal, Nezam
    Manus, Michael P.
    Jeffers, Lennox J.
    Nguyen, Tuan
    Berg, Thomas
    Dalekos, Georgios N.
    Trepo, Christian
    Roberts, Stuart K.
    Prieto, Martin
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A809 - A809
  • [33] The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)
    Manns, M.
    Jeffers, L.
    Dalekos, G.
    Berg, T.
    Trepo, C.
    Roberts, S.
    Prieto, M.
    Rizzetto, M.
    Sorbel, J.
    Anderson, J.
    Mondou, E.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S33 - S33
  • [34] PREDICTORS OF LIVER STIFFNESS CHANGES IN CHRONIC HEPATITIS B (CHB) PATIENTS UNDER LONG-TERM THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Kranidioti, Hariklia
    Protopapas, Adonis A.
    Voulgaris, Theodoros
    Tsolias, Chrisostomos
    Antonakaki, Pinelopi
    Deutsch, Melanie
    Triantos, Christos
    Goulis, John
    Papatheodoridis, George
    Manolakopoulos, Spilios
    GASTROENTEROLOGY, 2021, 160 (06) : S822 - S822
  • [35] TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL
    Berg, T.
    Moller, B.
    Trinh, H.
    Chan, S.
    Marcellin, P.
    Suarcz, E.
    Snow-Lampart, A.
    Oldach, D.
    Sorbel, J.
    Borroto-Esoda, K.
    Frederick, D.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S328 - S328
  • [36] Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
    Jeong, Sara
    Shin, Hyun Phil
    Kim, Ha Il
    INTERVIROLOGY, 2022, 65 (02) : 94 - 103
  • [37] Effect of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamideantiviral Therapy on Renal Function in Chronic Hepatitis B Patients: A Real-World Retrospective Study
    Li, Yu
    Li, Ya-Wei
    Gao, Ying
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2025, 18 : 1143 - 1153
  • [38] CORRELATIONS BETWEEN NON-INVASIVE BIOMARKERS AND FIBROSIS SCORES IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) AND TENOFOVIR ALAFENAMIDE (TAF) IN PHASE 3 CLINICAL TRIALS
    Ferret, Maria Asuncion Buti
    Gane, Edward J.
    Marcellin, Patrick
    Jacobson, Ira M.
    Janssen, Harry L. A.
    Agarwal, Kosh
    Fung, Scott K.
    Chuang, Wan-Long
    Pan, Calvin
    Flaherty, John F.
    Wang, Hongyuan
    Tan, Susanna
    Suri, Vithika
    Gaggar, Anuj
    Limw, Young-Suk
    Chan, Henry Lik Yuen
    HEPATOLOGY, 2020, 72 : 479A - 480A
  • [39] Randomized, Double-Blind, Placebo-Controlled Trial of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB)
    Chang, Mei-Hwei
    Park, Jae Hong
    Bezerra, Jorge A.
    Pacurar, Daniela
    Nijhawan, Sandeep
    Choe, Byung-Ho
    Kim, Kyung Mo
    Mehta, Rajiv M.
    Flaherty, John F.
    Wu, George
    Liu, Yang
    Reyes, Maribel
    Suri, Vithika
    Constantinescu, Alexandrina
    Choe, Yon-Ho
    Leung, Daniel H.
    HEPATOLOGY, 2018, 68 : 49A - 49A
  • [40] Characterization of HBsAg decline by genotype in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumurate (TDF) for up to 4 years
    Marcellin, P.
    Heathcote, E. J.
    Buti, M.
    Krastev, Z.
    Jacobson, I. M.
    De Man, R.
    Dusheiko, G. M.
    Zeuzem, S.
    Elsome, A. M.
    Barnes, C.
    Ng, C.
    Lou, L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 101 - 102
12345